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ABSTRACT 
 
Background: Increasing incidence and prevalence of end-stage renal disease (ESRD) together 
with the presence of several comorbidities in chronic kidney disease patients (CKD) could be 
associated with a relevant economic burden. 
Aim: The aim of this analysis was to estimate the direct healthcare costs of ESRD and its major 
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comorbidities in Italian patients who were naïve to hemodialysis (HD) recruited for the FARO-2 
study. 
Methods: The FARO-2 study was a retrospective observational study conducted in Italy that 
evaluated the patterns of treatment of secondary hyperparathyroidism (SHPT) and related costs in 
patients naïve to HD. The observational period was 2006–2008. Costs were measured in Euros 
(reference year: 2008). Resource use for the first 2 periods of 6 months of HD was monetized, with 
reimbursement calculated for SHPT drugs, phosphate binders, and erythropoietin-stimulating 
agents (ESAs); HD sessions; and hospitalizations due to ESRD and its major comorbidities. The 
analysis was performed by the Italian National Health Service (INHS) perspective. 
Results: 567 patients were observed for at least 2 periods of 6 months. During the first 12 months 
after the initiation of HD, average direct healthcare costs were assessed using the percentage of 
patients treated and the average daily dosages (for drugs), the percentage of patients hospitalized 
and the types of hospitalizations (for inpatients), and the average weekly frequency of HD 
sessions. Total per-patient yearly costs totaled 34,789.9 €: HD accounted for 66.1% of 
expenditures, with hospitalizations and drugs accounting for 12.9% and 21.0% of expenditures, 
respectively (including 17.1% for ESAs). 
Conclusions: Patients naïve to HD have a significant impact on Italian National Health Service 
expenditures, although only the costs related to treatment of ESRD and its comorbidities were 
calculated in the present study. The major cost drivers were HD and ESAs, while SHPT drugs and 
phosphate binders together accounted for only 3.9% of direct healthcare expenditures. 
 
 
Keywords: Cost of illness; cost of drugs; secondary hyperparathyroidism; hospitalizations; clinical 
practice. 
 
1.  INTRODUCTION 
 
The incidence and prevalence of end-stage renal 
disease (ESRD) are increasing worldwide  [1-5] 
due to the aging of the population, an increasing 
prevalence of type 2 diabetes mellitus and 
hypertension, and a trend toward early initiation 
of renal replacement therapies [6,7]. 
 
Increasing comorbidities related to worsening 
chronic kidney disease (CKD) [8-12] may be 
associated with a rapid rise in healthcare costs 
after the initiation of dialysis. As healthcare 
expenditures continue to increase, health 
authorities need to develop new strategies to 
rationalize expenditures and maintain the best 
standards of care. Understanding the causes of 
increases in healthcare costs is the first step to 
developing strategies to keep expenditure growth 
under control. Economic studies are needed in 
healthcare, mainly because the economic 
resources available to healthcare systems are 
not enough to cover the costs associated with all 
healthcare treatments and programs [13,14]. 
 
Several studies have analyzed the costs 
associated with patients undergoing HD, both 
internationally and in Italy [15-19] these studies 
have highlighted the significant burden of HD in 
terms of morbidity and mortality, and from an 
economic perspective, direct and indirect costs   
[20-23]. A few studies investigated the 
differences in healthcare costs from pre-dialysis 
to dialysis [24-26] and confirmed the dramatic 
increase in healthcare expenditures associated 
with the initiation of dialysis treatment. Several 
studies also explored the costs of the first few 
months of dialysis treatment [25,27,28] none of 
these studies, however, were carried out from 
the Italian perspective. The present study, 
conducted by the Italian National Health Service 
(INHS) perspective, aimed to evaluate healthcare 
costs related to ESRD and its major 
comorbidities in the first 12 months after initiating 
hemodialysis (HD). The INHS is an universalistic 
system that grants to all Italian citizens and legal 
foreign residents a coverage in terms of 
healthcare services. The INHS provides essential 
drugs, hospital accommodation and treatments, 
specialistic and general practitioners' visits, 
laboratory tests and diagnostic procedures. 
 
2. MATERIALS AND METHODS 
 
As described elsewhere [29-32], the FARO study 
was a prospective multicenter survey that 
evaluated treatment practices in 28 dialysis 
centers in Italy from April 2006 to October 2007; 
during the study, data on secondary 
hyperparathyroidism (SHPT) management and 
alignment with Kidney Disease Outcomes Quality 
Initiative (KDOQI) target ranges from all patients 
receiving HD were recorded. The FARO-2 study 
[33-35] was designed to integrate the data of the 
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Table 1. Sources for hospitalizations causes, reimbursement tariffs, and number of 
hospitalizations in Italy (2008) 
 
Causes of 
hospitalizations  
(as reported in the 
FARO-2 study) 
DRGs (code and description) DRG tariff 
(€)[36] 
Number of 
admissions[37] 
Cardiac complications 121: circulatory disorders with acute 
myocardial infarction, with major 
complications, discharged alive 
4,289.18 21,178 
122: circulatory disorders with acute 
myocardial infarction, without major 
complications, discharged alive 
3,416.01 33,397 
124: circulatory disorders except acute 
myocardial infarction with cardiac catheter, 
with complications 
3,741.88 33,811 
125: circulatory disorders except acute 
myocardial infarction with cardiac catheter, 
without complications  
1,795.17 64,938 
127: heart failure and shock 2,715.21 200,709 
Vascular complications 130: peripheral or vascular disorders with 
complications and/or comorbidities 
2,913.66 19,872 
131: peripheral or vascular disorders without 
complications and/or comorbidities 
1,320.40 21,609 
Cerebral complications 015: Transient ischemia  2,160.46 58,673 
016: nonspecific cerebrovascular disorders 
with complications and/or comorbidities  
3,253.07 26,457 
017: nonspecific cerebrovascular disorders 
without complications and/or comorbidities  
2,334.78 25,186 
014: specific cerebrovascular disorders 
except transient ischemic attack 
3,448.67 113,042 
Infections 320: kidney and urinary tract infections  
age >17 with complications and/or 
comorbidities 
2,307.02 14,765 
321: kidney and urinary tract infections  
age >17 without complications and/or 
comorbidities 
1,818.20 18,792 
Bone diseases 244: bone diseases and specific 
arthropathies with complications and/ 
or comorbidities 
2,455.17 4,029 
245: bone diseases and specific 
arthropathies without complications and/ 
or comorbidities 
1,743.50 11,602 
Diagnostic procedures in 
DH 
Day hospital 316: renal failure 266.81 4,479 
Anemia   395: red blood cell disorders age >17; 574: 
major hematologic/immunologic diagnosis 
except sickle cell crisis and coagulation 
disease 
2,054.84 44,021 
Hospitalization related to 
complications with 
arteriovenous fistula or 
Tesio catheter 
316: renal failure 3,482.69 75,065 
Hospitalizations related to 
kidney disease 
316: renal failure 3,482.69 75,065 
DRGs, Diagnosis-related group; DH, day-hospital 
 
FARO study by collecting the same data from 
patients naïve to treatment with HD. The FARO-2 
study included 26 dialysis centers operating 
within INHS that could be considered 
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representative of the Italian reality; patients 
selected for inclusion into the study had initiated 
dialysis during the FARO study and received 
dialysis treatment for ≤8 months. Data were 
collected retrospectively from 6 questionnaires, 4 
of which were completed during the FARO study 
and 2 that were collected during the FARO-2 
study (April–October 2008).  
 
For the present analysis, per-patient healthcare 
costs related to the treatment of ESRD and major 
comorbidities were estimated for the first and 
second periods of six months of dialysis 
treatment. The following cost parameters were 
monetized: Drugs (for the treatment of SHPT, 
phosphate binders and erythropoietin-stimulating 
agents [ESAs]), hospitalizations (for ESRD and 
comorbidities), and HD sessions. For the 
monetization of drugs, the public prices 
reimbursed by the INHS were used for drugs 
distributed by territorial pharmacies, whereas 
prices charged to the INHS were considered for 
drugs distributed through INHS structures 
(reference year: 2008). Costs related to hospital 
admissions for ESRD complications and major 
comorbidities were estimated based on INHS 
tariffs for the supply of hospital care (reference 
year: 2008), [36] weighted by the number of 
admissions in Italy for 2008, [37] as reported in 
Table 1.  
 
HD costs were estimated based on the Italian 
national tariffs that were in effect during the 
study. [38] The average cost per patient was 
defined as the sum of the costs of drugs, 
hospitalizations, and HD. In order to obtain the 
average daily per-patient cost of drugs, the daily 
drug cost was multiplied by the average daily 
dosages and percentages of patients treated; for 
inpatients, the average cost of each 
hospitalization was weighted by the percentage 
of patients hospitalized in order to estimate the 
average per-patient cost for hospitalization; for 
HD, the average weekly frequency of HD was 
multiplied by its unitary tariff.  
 
3. RESULTS  
 
A total of 568 patients were recruited in the 
FARO-2 study [mean age 65.5±15.2 (SD)]; of 
these patients 134 (23.6%) had diabetes. 567 
patients were still in the study during the second 
period of six months of observation. In the first 2 
period of six months after the initiation of dialysis, 
oral (PO) calcitriol, intravenous (IV) calcitriol, IV 
paricalcitol, and PO cinacalcet were used for the 
treatment of SHPT; calcium acetate, calcium 
carbonate, sevelamer, and lanthanum carbonate 
were used as phosphate binders. The vast 
majority (more than 93%) of patients were also 
treated with ESAs. The average dosages per 
drug and the percentages of patients treated in 
the 2 periods of six months following HD 
treatment initiation are reported in Table 2. 
 
As was previously reported in the FARO study, 
the average weekly dose of paricalcitol 
decreased over time (from 13.10 mcg/week 
during the first period of six months to 10.66 mcg 
in the second period of six months). Aluminum 
hydroxide was used in 15.5% of patients during 
the first period of six months of observation; 
however, its use was not monetized because it 
was not charged to the INHS. The average per-
patient costs of hospitalizations related to ESRD 
and its comorbidities are reported in Table 3.  
 
During the first period of six months of HD, 
approximately 40% of patients were admitted to 
the hospital with a diagnosis related to kidney 
disease and 17% were admitted because of 
complications related to the arteriovenous fistula 
or Tesio catheter; the most frequent 
complications related to hospitalization were 
cardiac complications (more than 9% of patients 
during the first period of six months), followed by 
vascular complications (more than 4%). In the 
second period of six months, hospitalizations due 
to kidney disease decreased to approximately 
6%, while admissions related to complications 
from the arteriovenous fistula or Tesio catheter 
increased to approximately 26%. 
 
The frequency of dialysis sessions during the 2 
periods of six months remained stable, with 
approximately 80% of patients undergoing 3 
dialysis sessions/week; average per-patient 
costs linked to HD, weighted by the percentage 
of patients undergoing 3, 2, or 1 dialysis 
session/week was 433.7 €/week during the first 
period of six months and 449.8 €/week during the 
second period of six months. 
 
Overall, the total cost per patient in the first 
period of six months, including SHPT drugs, 
phosphate binders, ESAs, hospitalizations 
related to ESRD, comorbidities, and HD sessions 
was 17,404.4 €, whereas in the second  period of 
six months, the cost per patient was 17,358.5 €. 
On a yearly basis, ESRD-related direct 
healthcare costs were estimated to be 34,762.9 
€. 
 
Cost breakdowns per period of six months are 
reported in Table 4. 
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Table 2. Drugs usage during the first 2 period of six months of dialysis 
 
  
  
First six months period Second six months period 
Percentage 
of patients 
treated 
Average dosages (± SD) Percentage 
of patients 
treated 
Average dosages (± SD) 
SHPT drugs 
        
PO calcitriol 68.60% 1.72 mcg/week (1.11) 65.50% 1.59 mcg/week (0.81) 
IV calcitriol 6.10% 2.18 mcg/week (0.87) 5.40% 2.54 mcg/week (0.66) 
IV paricalcitol 20.30% 13.10 mcg/week (10.69) 27.90% 10.66 mcg/week (5.93) 
Cinacalcet 0.90% 37.50 mg/die (15.00) 2.60% 38.33 mg/die (23.43) 
Phosphate binders 
        
Calcium acetate 3.70% 1,690.50 mg/die (749.6) 4.80% 2,187.00 mg/die (1,101.71) 
Calcium carbonate 49.50% 1,885.10 mg/die (933.79) 44.60% 2,114.40 mg/die (1,228.61) 
Sevelamer 26.10% 3,257.30 mg/die (1,366.94) 29.30% 3,703.10 mg/die (1,694.80) 
Lanthanum 
carbonate 
0.00%   0.90% 1,250.00 mg/die (500.00) 
ESAs 93.50% 11,132.00 UI/week 
(7,596.22) 
93.60% 10,884.00 UI/week 
(8,312.76) 
ESA, erythropoetin-stimulating agent; IV, intravenous; PO, by mouth; SD, standard deviation; SHPT, secondary 
hyperparathyroidism 
 
Table 3. Hospitalizations related to ESRD and its associated comorbidities during the first 2 
periods of six months of dialysis 
 
 Causes of hospitalization  First six months period Second six months period 
Percentage 
of patients 
hospitalized 
Average per- 
patient cost 
weighted by the 
% of use (€) 
Percentage of 
patients 
hospitalized 
Average per- 
patient cost 
weighted by the 
% of use (€) 
Cardiac complications 9.40 263.64 11.40 319.73 
Vascular complications 4.40 91.68 6.90 143.77 
Cerebral complications 2.80 82.92 5.70 168.81 
Infections 1.10 22.37 5.10 103.70 
Bone diseases 0.00 0.00 3.40 65.52 
Diagnostic procedures in DH 0.60 1.60 2.30 6.14 
Anemia   1.70 34.93 1.70 34.93 
Hospitalizations related to 
arteriovenous fistula or Tesio 
catheter 
17.10 595.54 26.30 915.95 
Hospitalizations related to 
kidney disease 
40.90 1,424.42 6.30 219.41 
Average per-patient cost (€)   2,517.10      1,977.95    
ESRD, end-stage renal disease; DH, day-hospital 
 
Table 4. Breakdown of per-patient costs in first 2 periods of six months 
 
  First period of six months 
(€) 
Second period of six months 
(€) 
SHPT drugs 324.02  381.40  
Phosphate binders 282.99  363.75  
ESAs 3,004.66  2,940.86  
HD 11,275.60  11,694.56  
Hospitalizations 2,517.10 1,977.95  
Total 17,404.37  17,358.52 
ESA, erythropoetin-stimulating agent; HD, hemodialysis; SHPT, secondary hyperparathyroidism 
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During the year studied in the present analysis, 
costs for HD sessions accounted for 
approximately 66% of the total costs and 
hospitalizations accounted for 13% of the total 
costs; among drugs, which as a whole accounted 
for 21% of the total costs, ESAs represented 
more than 80% of ESRD drug expenditures (17% 
of total expenditures). 
 
4. DISCUSSION 
 
For the first time, through the FARO-2 study, it 
was possible to collect data on the costs related 
to ESRD treatment and major comorbidities in 
Italy by analyzing real-world practice. As 
expected, even if patients with ESRD had 
relevant comorbidities, HD sessions represented 
the major cost drivers in patients beginning HD 
and undergoing 3 dialysis sessions/week on 
average. The relevance of dialysis sessions as a 
cost driver has been confirmed by other national 
and international studies, although these studies 
were not focused on patients who are new to HD 
treatment [39,24,18-20]. 
 
The results of the present analysis cannot be 
compared with the data previously published by 
Salonen et al. [27] as the present study is 
focused on patients undergoing HD and takes 
into account only direct healthcare costs related 
to ESRD and its comorbidities, not all healthcare 
costs (regardless of their relation to ESRD). In a 
study conducted by Coentrão et al. [28] in 
Portugal, the costs for HD sessions were not 
considered and patients undergoing HD were 
analyzed separately (patients with arteriovenous 
fistula or Tesio catheter); this makes any 
comparisons with the present study speculative 
at best. Because of the relevant differences in 
healthcare coverage, published US data [25] on 
patients undergoing dialysis are not comparable 
with the present study. 
 
Major limitations of the FARO-2 are related to the 
design of the study, which was uncontrolled. 
However, the study reflects real-world practice in 
Italy in 2006–2008. Moreover, due to its study 
design, the FARO-2 study provided detailed 
information on resource consumption only for the 
week preceding each survey (specifically 
regarding drugs dosages); consequently, some 
data were extrapolated to the period covering 2 
different surveys. The data on SHPT drugs and 
phosphate binders utilization included in the 
present study may have been influenced by the 
period of study itself (the use of lanthanum 
carbonate, for example, increased significantly in 
the following period of six months because of the 
recent commercialization); however, this reflects 
real-world practice during the study. Major 
strengths of the study are the sample size, the 
number of participating dialysis centers, and the 
non-interventional nature of the study, which 
provided insight into the real-world patterns of 
treatment during the study period. 
 
5. CONCLUSIONS 
 
Patients who are naïve to HD have a significant 
impact on INHS expenditures, even when only 
costs related to ESRD treatment and its 
comorbidities are taken into account. On a yearly 
basis, average per-patient costs were estimated 
to be 34,762.9 €; and HD sessions represented 
the major cost driver (approximately 66%). Drug 
costs represented about 21% of the total costs, 
with ESAs representing more than 80% of this 
expenditure; SHPT drugs and phosphate binders 
accounted for only approximately 4% of per-
patient costs. 
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